{"prompt": "['Page 1 of 60', '1', 'TITLE PAGE', 'VERTEX', 'VERTEX PHARMACEUTICALS INCORPORATED', 'Clinical Study Protocol', 'A Phase 3b, Randomized, Double-blind, Controlled', 'Study Evaluating the Efficacy and Safety of', 'VX-445/Tezacaftor/lvacaftor in Cystic Fibrosis', 'Subjects, Homozygous for F508del', 'Vertex Study Number: VX18-445-109', 'EudraCT Number: 2019-001735-31', 'Date of Protocol: 30 May 2019 (Version 1.0)', 'Vertex Pharmaceuticals Incorporated', '50 Northern Avenue', 'Boston, MA 02210-1862, USA', 'CONFIDENTIAL', 'This document contains confidential information. Any use, distribution, or disclosure without the prior written consent', 'of Vertex Pharmaceuticals Incorporated is strictly prohibited except to the extent required under applicable laws or', 'regulations. Persons to whom the information is disclosed must be informed that the information is confidential and', 'may not be further disclosed by them.']['Protocol VX18-445-109, Version 1.0', 'Page 2 of 60', '2', 'PROTOCOL SYNOPSIS', 'Title A Phase 3b, Randomized, Double-blind, Controlled Study Evaluating the Efficacy', 'and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous', 'for F508del', 'Brief Title', 'A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic', 'Fibrosis Subjects, Homozygous for F508del', 'Clinical Phase and', 'Phase 3b, efficacy and safety', 'Clinical Study Type', 'Objectives', 'Primary Objective', 'To evaluate the efficacy of VX-445/tezacaftor (TEZ)/ivacaftor (IVA) in cystic', 'fibrosis (CF) subjects, homozygous for F508del (F/F).', 'Secondary Objectives', 'To evaluate the safety of VX-445/TEZ/IVA', 'To evaluate the pharmacodynamics (PD) of VX-445/TEZ/IVA', 'Endpoints', 'Primary Endpoint', 'Absolute change in CF Questionnaire-Revised (CFQ-R) respiratory domain score', 'from baseline through Week 24', 'Key Secondary Endpoint', 'Absolute change in percent predicted forced expiratory volume in 1 second', '(ppFEV1) from baseline through Week 24', 'Secondary Enppoints', 'Absolute change in sweat chloride (SwCl) from baseline through Week 24', 'Safety and tolerability assessments based on adverse events (AEs), clinical', 'laboratory values, ECGs, vital signs, and pulse oximetry', 'Number of Subjects', 'Up to approximately 158 subjects will be randomized (1:1) to either the', 'VX-445/TEZ/IVA group or the TEZ/IVA group.', 'Study Population', 'Male and female CF subjects who are 12 years of age or older and have an F/F', 'genotype', 'Investigational Drug', 'During the TEZ/IVA Run-in Period, study drug refers to TEZ/IVA and IVA.', 'During the Treatment Period, study drug refers to VX-445/TEZ/IVA and matching', 'placebo, TEZ/IVA and matching placebo, and IVA.', 'Active study drugs will be orally administered as fixed-dose combination (FDC)', 'film-coated tablets (either VX-445/TEZ/IVA or TEZ/IVA) in the morning and as a', 'film-coated IVA tablet in the evening.', 'Active substance: VX-445/TEZ (VX-661)/IVA (VX-770)', 'Vertex Pharmaceuticals Incorporated']['Protocol VX18-445-109, Version 1.0', 'Page 3 of 60', 'Activity: CFTR corrector, CFTR corrector, and CFTR potentiator', 'Strength: 100 mg/50mg/75 mg', 'Active substance: TEZ (VX-661)/ IVA (VX-770)', 'Activity: CFTR corrector and CFTR potentiator', 'Strength: 100 mg/150 mg', 'Active substance: IVA (VX-770)', 'Activity: CFTR potentiator', 'Strength: 150 mg', 'Study Duration', 'The total study duration is approximately 36 weeks (4 weeks for the Screening', 'Period, 4 weeks for the TEZ/IVA Run-in Period, 24 weeks for the Treatment Period,', 'and 4 weeks for the Safety Follow-up Period).', 'Study Design', 'This is a Phase 3b, randomized, double-blind, active-controlled, parallel-group,', 'multicenter study (Figure 2-1).', 'Figure 2-1', 'Schematic of the Study Design', 'Treatment Period', 'VX-445/TEZ/IVA Group', 'N 79', 'TEZ/IVA', 'Screening', 'Run-in', 'Safety', 'Period', 'Period', 'Follow-up', 'TEZ/IVA Group', 'N 79', 'Day -56', 'Day -28', '24 Weeks', '28 days', 'to Day -29', 'to Day -1', '(Day 1 to Week 24)', 'Randomization', 'Open-label Study', 'IVA: ivacaftor; N: number of subjects; TEZ: tezacaftor', 'Note: The Safety Follow-up Visit is not required for subjects who complete the Week 24', 'Visit and have enrolled in an open-label study within 28 days after the last dose of study', 'drug.', 'In the TEZ/IVA Run-in Period, all subjects will receive TEZ 100 mg once daily', '(qd)/IVA 150 mg every 12 hours (q12h). After completing the TEZ/IVA Run-in', 'Period, subjects will be randomized (1:1) to the VX-445/TEZ/IVA group or TEZ/IVA', 'group for the Treatment Period (Table 2-1).', 'Table 2-1', 'Treatment Period Groups and Dosages', 'Treatment Group', 'VX-445 Dosage', 'TEZ Dosage', 'IVA Dosage', 'VX-445/TEZ/IVA', '200 mg qd', '100 mg qd', '150 mg q 12h', 'TEZ/IVA', '0 mg qd', '100 mg qd', '150 mg q 12h', 'IVA: ivacaftor; q 12h: every 12 hours; qd: once daily; TEZ: tezacaftor', 'Randomization will be stratified by ppFEV1 determined during the TEZ/IVA Run-in', 'Period (Day -14 assessment; <70 versus 70), age at the Screening Visit (<18 versus', '>18 years of age), and whether the subject is receiving CFTR modulator treatment at', 'the Screening Visit (yes versus no). If the Day - -14 ppFEV1 value is not valid or not', 'Vertex Pharmaceuticals Incorporated']\n\n###\n\n", "completion": "END"}